A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Filgrastim; Paclitaxel; Pegfilgrastim
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms KEYNOTE-522
- Sponsors Merck Sharp & Dohme
- 28 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated
- 09 Jul 2018 Planned primary completion date changed from 21 Sep 2018 to 1 Nov 2018.